Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ADPT logo ADPT
Upturn stock ratingUpturn stock rating
ADPT logo

Adaptive Biotechnologies Corp (ADPT)

Upturn stock ratingUpturn stock rating
$11.65
Last Close (24-hour delay)
Profit since last BUY16.15%
upturn advisory
Consider higher Upturn Star rating
BUY since 39 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ADPT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $11.86

1 Year Target Price $11.86

Analysts Price Target For last 52 week
$11.86Target price
Low$3.3
Current$11.65
high$12.43

Analysis of Past Performance

Type Stock
Historic Profit -43.17%
Avg. Invested days 29
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.79B USD
Price to earnings Ratio -
1Y Target Price 11.86
Price to earnings Ratio -
1Y Target Price 11.86
Volume (30-day avg) 8
Beta 1.79
52 Weeks Range 3.30 - 12.43
Updated Date 06/30/2025
52 Weeks Range 3.30 - 12.43
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.95

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -74.84%
Operating Margin (TTM) -56.45%

Management Effectiveness

Return on Assets (TTM) -15.05%
Return on Equity (TTM) -61.03%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1684574152
Price to Sales(TTM) 9.45
Enterprise Value 1684574152
Price to Sales(TTM) 9.45
Enterprise Value to Revenue 8.89
Enterprise Value to EBITDA -1
Shares Outstanding 151916992
Shares Floating 103894327
Shares Outstanding 151916992
Shares Floating 103894327
Percent Insiders 2.35
Percent Institutions 98.36

Analyst Ratings

Rating 3
Target Price 11.86
Buy 4
Strong Buy 3
Buy 4
Strong Buy 3
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Adaptive Biotechnologies Corp

stock logo

Company Overview

overview logo History and Background

Adaptive Biotechnologies was founded in 2009. It focuses on leveraging the adaptive immune system to develop diagnostics and therapeutics. Initially focused on research, it has expanded into commercial applications.

business area logo Core Business Areas

  • Therapeutics: Developing novel T-cell receptor (TCR)-based therapeutics for cancer and other diseases.
  • Minimal Residual Disease (MRD) Diagnostics: Providing clonoSEQ assays for detecting and monitoring minimal residual disease in blood cancers.
  • Drug Discovery: Using its immune medicine platform to discover novel drug targets and develop new therapies.

leadership logo Leadership and Structure

The leadership team includes CEO and various VPs heading different departments. The company is structured with distinct divisions for diagnostics, therapeutics, and research.

Top Products and Market Share

overview logo Key Offerings

  • clonoSEQ: clonoSEQ is a test to detect and monitor minimal residual disease (MRD) in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Competitors include Invitae (NVTA) and Labcorp (LH).
  • T-Detect: T-Detect is a test to detect prior or present T cell immune response to certain pathogens and diseases such as COVID-19. No specific market share data is available. Competitors include Quanterix (QTRX) and PerkinElmer (PKI).

Market Dynamics

industry overview logo Industry Overview

The diagnostics and therapeutics market is experiencing growth, driven by technological advancements and increasing demand for personalized medicine.

Positioning

Adaptive Biotechnologies is positioned as an innovative company leveraging the adaptive immune system for diagnostics and therapeutics, with a focus on personalized medicine. Its competitive advantages include a robust technology platform and strategic partnerships.

Total Addressable Market (TAM)

TAM estimated in billions of dollars. Adaptive Biotechnologies is positioned to capture a portion of the MRD testing and immune-driven therapy markets.

Upturn SWOT Analysis

Strengths

  • Proprietary immune medicine platform
  • Strategic partnerships with leading pharmaceutical companies
  • Established clonoSEQ diagnostic product
  • Strong intellectual property portfolio

Weaknesses

  • Limited profitability
  • Dependence on partnerships for revenue
  • High research and development costs
  • Limited commercial infrastructure

Opportunities

  • Expansion into new therapeutic areas
  • Increased adoption of MRD testing
  • Development of new diagnostic products
  • Leveraging data insights for drug discovery

Threats

  • Competition from established diagnostic companies
  • Regulatory hurdles for new products
  • Technological obsolescence
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • INVITAE CORP (NVTA)
  • GUARDANT HEALTH INC (GH)
  • NATERA INC (NTRA)

Competitive Landscape

Adaptive Biotechnologies faces competition from larger, more established diagnostic companies. Its advantage lies in its unique technology platform and focus on personalized medicine.

Major Acquisitions

No recent major acquisitions

  • Year: 2023
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: N/A

Growth Trajectory and Initiatives

Historical Growth: Historical growth can be assessed using past revenue and profit figures (available in past financial reports).

Future Projections: Future growth projections can be obtained from analyst reports and company guidance.

Recent Initiatives: Recent initiatives include partnerships for therapeutic development and expansion of diagnostic testing services.

Summary

Adaptive Biotechnologies is an innovative company pioneering immune-driven diagnostics and therapeutics. While possessing a strong technology platform and strategic partnerships, its profitability remains a concern. Growth opportunities exist in expanding its product line and therapeutic applications. It must navigate competition and regulatory hurdles to achieve sustainable success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Adaptive Biotechnologies Corp

Exchange NASDAQ
Headquaters Seattle, WA, United States
IPO Launch date 2019-06-27
Co-Founder, CEO & Chairman Mr. Chad M. Robins M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 619
Full time employees 619

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.